Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT

Ruf, Juri; Steffen, Ingo G.; Mehl, Sebastian; Rosner, Christian; Denecke, Timm; Pape, Ulrich‐Frank; Plotkin, Michail; Amthauer, Holger

doi:10.1097/mnm.0b013e3282efa1a9

Cited by 26 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…111 Indium) or by positron emission tomography (PET; e.g. 68 Gallium) scanning [42,43,44,45,46,47,48,49,50,51,52,53,54]. For Si-NEN PET scanning, the use of 18 fluorodeoxyglucose cannot be recommended, since it has a low sensitivity for well-differentiated low-grade NEN, which comprise by far the majority of Si-NENs.…”

Section: Imagingmentioning

confidence: 99%

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

et al. 2016

View full text Add to dashboard Cite

Section: Imagingmentioning

confidence: 99%

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

et al. 2016

View full text Add to dashboard Cite

“…As we further explain in the following section, CT coregistration has been reported to improve the localization of the lesions, thanks to the attenuation correction [43][44][45].…”

Section: Somatostatin Receptor Scintigraphic Imagingmentioning

confidence: 99%

Somatostatin receptor SPECT

Pepe

Moncayo

Bombardieri³

et al. 2012

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.

show abstract

“…The impact of AC on SRS SPECT data in patients examined by hybrid SPECT/CT has been evaluated in two studies. In the first one, 17 patients with NETs were considered: the intensity and contrast of 46 foci classified as pathological were rated in both the non-attenuation corrected (NAC) and the AC SPECT images [36]. Focus contrast and intensity significantly increased in 14 out of 46 foci (30 %) after AC in the visual analysis, with increasing focus depth.…”

Section: In-111 Pentetreotide Spect/ctmentioning

confidence: 99%

SPECT/CT in neuroendocrine tumours

Schillaci

Spanu

Palumbo

et al. 2014

Clin Transl Imaging

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms with very varying clinical expressions. Nuclear medicine plays an important role in the imaging and treatment of these tumours. Despite the advent of several PET radiopharmaceuticals, SPECT imaging with the labelled somatostatin receptor analogue In-111 pentetreotide or with radioiodinated MIBG is still a very useful technique for evaluating patients with NETs. The aim of this review is to summarise the applications, in the study of NETs, of hybrid SPECT/CT imaging performed using these gamma-emitting radiopharmaceuticals. The combined use of SPECT and CT in hybrid devices is of value when applied to scintigraphic procedures in NETs: the addition of anatomical maps provides a precise localisation of SPECT findings and allows the exclusion of disease in sites of physiological tracer uptake. These advantages translate into better sensitivity and specificity, both of which are essential for the diagnosis and accurate staging of NETs. SPECT/CT hybrid images are able to provide additional information that improves the diagnostic accuracy and confidence of SPECT interpretation and leads to changes in therapeutic options in about 25 % of patients. Therefore, SPECT/CT should be routinely performed and considered standard practice in the diagnostic work-up and treatment planning of patients with NETs submitted to In-111 pentetreotide or radioiodinated MIBG imaging. This approach can still be used as an alternative to PET/CT options when the latter are not available.

show abstract

Influence of attenuation correction by integrated low-dose CT on somatostatin receptor SPECT

Abstract: Attenuation correction of SRS SPECT data by SPECT-CT results in visually more clearly contrasted foci. Moreover, as focus intensity increases, especially in the more centrally localised foci, CT-based AC has a potential to further improve the sensitivity of SRS SPECT.

Cited by 26 publications

References 16 publications

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Somatostatin receptor SPECT

SPECT/CT in neuroendocrine tumours

Contact Info

Product

Resources

About